Articles tagged with Schizophrenia
Digital phenotyping approaches combine smartphone data analysis and machine learning to monitor patients with psychosis spectrum illnesses. Researchers identified promising tools for care improvement, calling for larger studies and expanded efforts in early diagnosis and treatment.
The research will develop biomarkers and clinical assessments to improve treatment outcomes for adolescents and young adults at risk of schizophrenia. The five-year study will recruit 1,040 patients with Clinical High Risk (CHR) and healthy controls, using data-driven methods to predict individual clinical trajectories.
Researchers found that depression is an intrinsic part of early phase psychotic disorders and suggest targeting depression as a key factor in treatment. The study suggests antidepressants alongside anti-psychotic drugs could be an effective additional first-line treatment for psychosis.
Researchers at the University of Tokyo have developed a machine learning algorithm that can distinguish between different psychiatric diagnoses, including autism spectrum disorder and schizophrenia. The algorithm uses MRI brain scans to identify variations in brain thickness, surface area, or volume.
Researchers at Kumamoto University found that DNA methylation in the serotonin transporter gene is inversely correlated with amygdala volume in male patients with schizophrenia and bipolar disorder. The study suggests a potential biomarker for onset prediction, diagnosis, and therapeutic effects.
Researchers at UMBC develop independent vector analysis (IVA) for common subspace extraction (CS) to analyze fMRI data, identifying subgroups of schizophrenia patients with significant clinical significance. The method preserves nuances in data while rendering statistically significant groupings.
A study of 75,000 patients with schizophrenia spectrum disorders found that those who experienced a mood disorder or hospitalization prior to diagnosis were at the highest risk for suicide. The researchers suggest increasing age limits for first episode psychosis programs and extending clinical follow-up care as potential solutions.
Researchers discovered a link between NMDA receptor dysfunction and sleep spindle deficit in schizophrenia. Medicines targeting these receptors may help treat psychiatric disorders, such as psychosis.
A new UC San Francisco study found that precise synchronization of high-frequency brain waves is crucial for learning to let go of old rules and make way for new updates. Disrupting these synchronized waves can lead to perseverative behaviors, a common symptom in schizophrenia.
Recent genome-wide association studies identify genetic variants associated with schizophrenia, promising new treatments targeting the underlying biology and pathophysiology of the disorder. Researchers review efforts to bridge the gap between genetic findings and innovative treatments.
Research found that complement gene variants contribute to sex-based differences in vulnerability to autoimmune diseases lupus and Sjögren's syndrome, as well as mental disorder schizophrenia. Complement protein levels vary between men and women, with different age-related elevations and effects on disease incidence.
Researchers identified novel region-specific molecular markers for targeting specific subpopulations of dopamine D2 receptor neurons in the striatum, revealing functional specificity among these neuron populations. The study found that D2 neurons in different areas of the brain express distinct proteins and exhibit altered functions.
A recent study has identified the complement component 4 (C4) gene as a key factor in understanding sex biases in autoimmune disorders and schizophrenia. Individuals with more C4 genes were found to be less likely to develop autoimmune conditions but more likely to develop schizophrenia.
Researchers discovered a deficiency in S1P, a type of fatty molecule, in schizophrenia patients' brains. Preventing S1P degradation might lead to new treatments for the disorder, which affects one in three patients with ineffective current therapies.
A genetic change, known as Copy Number Variation, has been found to increase the risk of developing schizophrenia. The study reveals that this change affects brain areas and inhibitory neurons involved in schizophrenia, highlighting a potential target for drug treatment.
Researchers have identified extremely rare variants that affect the boundaries of a 3D genome structure called topologically associated domains (TADs) in people with schizophrenia. These variants may contribute to dysregulation of gene expression, leading to the development of the disease.
A recent study published in PLOS ONE found that tackling unhealthy lifestyle factors can provide the greatest benefit in increasing life expectancy among those with severe mental illness. Interventions aimed at stopping smoking and reducing sedentary behavior show promise, with potential increases of 2 years and 1 year, respectively.
A new study led by NUI Galway researchers provides insights into the neural basis of general cognitive ability (IQ) and its relationship with brain structure and schizophrenia. The research used diffusion tensor imaging to analyze brain scans and measures of cognitive function in over 1,700 participants.
A novel imaging marker has been developed to help diagnose and treat schizophrenia, using abnormal striatal function as a promising biomarker. The study, published in Nature Medicine, shows that this biomarker can distinguish between schizophrenia patients and healthy controls, while also predicting treatment response.
Yale researchers identified a critical molecule in prefrontal cortex circuits that enables working memory. Activating this receptor may offer potential treatments for neurocognitive disorders like schizophrenia and Alzheimer's disease.
A study published in the journal Brain found that nearly 40% of schizophrenia patients had brains similar to those of healthy people, highlighting a potential new subtype. The discovery could lead to more personalized treatment options by accounting for these differences.
Researchers at the University of Birmingham suggest integrating various theories to inform clinical practice. They propose a new approach that acknowledges patients' sense of self is disrupted in schizophrenia. By focusing on how patients can lead fulfilling lives with their symptoms, clinicians can improve treatment outcomes.
A study found that prenatal hypoxia may contribute to schizophrenia by altering the functioning of astrocytes and mitochondria. Researchers investigated the effects of hypoxia on rat astrocytes and observed changes in mitochondrial calcium balance, which can lead to cell death.
Scientists at St. Jude Children's Research Hospital have identified two critical microRNAs driving ventricular enlargement in models of schizophrenia. Reduced expression of these microRNAs leads to increased motile cilia movement and brain ventricle enlargement, highlighting a potential target for future treatments.
A new study analyzing MRI scans of individuals with 22q11.2 deletion syndrome found significant brain volume differences compared to control groups, including lower volumes in specific structures and higher volumes in others. The study provides a unique window into how psychiatric problems develop over time.
A Stony Brook University-led study finds that early intervention in schizophrenia does not improve long-term outcomes, contradicting common views. Comprehensive care has been shown to reduce symptoms and improve mental health, but treatment effects may be overstated due to lead-time bias.
Researchers found participants with schizophrenia carry damaging genetic mutations affecting brain and synaptic function, disrupting neural pathways that elevate risk. This discovery informs understanding of schizophrenia across human populations and suggests potential mechanisms for more effective treatments.
Researchers analyzed genetics of schizophrenia in South African Xhosa population, finding rare genetic mutations linked to the disorder. The study sheds light on potential mechanisms for effective treatments and informs understanding of schizophrenia across human populations.
A genetic study of schizophrenia in South African Xhosa individuals reveals a higher prevalence of rare damaging mutations in those with the disorder. The findings provide insights into the universal nature of human biology and can inform new treatments for schizophrenia.
A University of Georgia psychologist's study confirms that treating avolition, a motivation-related symptom, improves other negative symptoms of schizophrenia. The results suggest targeting this domain could improve overall negative symptoms and reduce functional disability.
A University of Miami study has found that the profiles of genes influencing cognition are similar across people with schizophrenia, bipolar disorder, and the general population. This discovery could lead to more effective therapies for improving cognitive function in patients with severe mental illness.
Researchers detect lower levels of a protein found in brain connections in people with schizophrenia, which could underlie cognitive difficulties and provide targets for new treatments. The study's findings suggest that loss of synapses may be linked to the development of schizophrenia.
A study found that an overactive immune system gene causes schizophrenia-like changes in mice, including neural and behavioral aspects of the disease. The researchers suggest that this gene may be contributing to the development of schizophrenia through mis-regulated synaptic pruning.
A 20-year study found that long-term antipsychotic treatment significantly reduced mortality in people with schizophrenia compared to those without medication. The study also showed no increased risk of hospitalization for cardiovascular disease among those receiving antipsychotic therapy.
A study of 1.3 million people found shared genetic factors between body mass index and major psychiatric disorders like schizophrenia, bipolar disorder, and major depression. Obesity is a risk factor for cardiovascular disease, which contributes to a shorter life expectancy among those with psychiatric disorders.
A recent study published in JAMA Network Open found that children exposed to high levels of air pollution during childhood are at a higher risk of developing schizophrenia. The study showed an increased risk of approximately 20% for every 10 μg/m3 increase in daily average air pollution.
A study from Johns Hopkins Medicine suggests that being around dogs from an early age may have a health benefit, decreasing the chance of developing schizophrenia as an adult. However, no significant link was found between dogs and bipolar disorder or cats and either psychiatric disorder.
A new hypothesis identifies a common link between schizophrenia and pellagra, suggesting that some people with psychosis in poorer nations may have a vitamin B3 deficiency. This could lead to better diagnosis, treatment, and potential cure of psychosis through niacin supplementation.
A new study by UNC researchers found that using a polygenic risk score (PRS) improves psychosis risk prediction in persons meeting clinical high-risk criteria. The PRS, developed from genome-wide association studies (GWAS), discriminates persons with schizophrenia from unaffected individuals and predicts future psychosis.
A study of over 24,000 Swedish adults found that those with a family history of schizophrenia and lower IQ are more likely to experience treatment-resistant schizophrenia. The condition is associated with higher risk for suicide and significant health costs.
A new study published in Psychological Medicine found that tobacco smoking may increase the risk of developing depression and schizophrenia. The researchers used UK Biobank data from 462,690 individuals and applied Mendelian randomization to analyze the association between smoking and mental illness.
A study found that a subtype of schizophrenia is related to abnormal hydrogen sulfide levels in the brain, which can act as a biomarker. Higher than normal levels of the enzyme Mpst were detected in postmortem brains and hair follicles from people with schizophrenia.
Researchers discovered a link between SETD1A gene mutations and schizophrenia risk in mice. Restoring the gene's function reversed behavioral and neuronal abnormalities, suggesting potential treatment strategies.
Researchers create wireless device to objectively assess social behavior and physical distance of people with schizophrenia, aiming to personalize treatment options. The device uses acoustic signals and GPS capabilities to collect data, which will be analyzed to find correlations with symptoms.
A large-scale study implicates 10 new genes in the development of schizophrenia, providing insights into the genetic underpinnings of the disorder. The findings also suggest a connection between schizophrenia and other neurodevelopmental disorders.
Researchers restored normal working memory to a mouse model of schizophrenia, eliminating a core symptom that has proven virtually impossible to treat. The findings, published in Neuron, hold immense promise for treating over 21 million people diagnosed with schizophrenia.
Researchers found significantly reduced mu-opioid receptor levels in schizophrenia patients' brains, contributing to negative feelings. This discovery provides a promising new lead for developing treatments for the condition.
Researchers found that patients with schizophrenia who experienced auditory hallucinations had abnormal tonotopic organization of the auditory cortex, established in infancy. This suggests that the vulnerability to develop 'voices' is probably established many years before symptoms begin.
Researchers discovered that gene expression regulators work together to raise an individual's risk of developing schizophrenia. The study found that modeled gene expression changes matched those found in patients' brains, highlighting the importance of considering complex genetic interactions in psychiatric disorders.
A study has identified TCF4 as a master regulator of schizophrenia during early human brain development. The gene is believed to play a crucial role in the disease's underlying genomic biology. Researchers hope that this discovery will pave the way for new treatments and precision medicine approaches.
A prize has been awarded to researchers who investigated an experimental schizophrenia drug that didn't improve cognitive function but had a good safety profile. The study will inform the development of other treatments for patients with schizophrenia, including potential applications in other disease areas.
A world-first review of 10,951 people with mental health disorders found strong evidence for omega-3 supplements as an add-on treatment for major depression. Emerging evidence also supports N-acetylcysteine and certain folate supplements for mood disorders and schizophrenia.
A dietary supplement called sarcosine may help people with schizophrenia by improving glutamate receptor function. Researchers urge clinical trials to confirm its effectiveness and establish guidelines for its use.
The study reveals that auditory sensory gating filtering begins at the brainstem, contradicting earlier hypotheses. This finding has significant implications for understanding schizophrenia, a condition characterized by difficulty prioritizing and ranking sounds.
Researchers found that people with schizophrenia employ different brain circuits to overcome initial lack of understanding, leading to increased brain activity in certain areas. The study aims to develop practical skills to help patients with schizophrenia understand metaphors in everyday speech.
A new study found that schizophrenia's neurobiological mechanisms vary between males and females, with many genes related to the illness expressed differently in each. This suggests that sex-specific treatments may be necessary to address the different underlying causes of schizophrenia in males and females.
A systematic review and meta-analysis found that refugees may be at higher risk of developing nonaffective psychosis, including several types of schizophrenia, compared to natives or nonrefugee migrants in host countries. The study analyzed data from over 540,000 refugees in Denmark, Sweden, Norway, and Canada.
Researchers have found that gene expression patterns in the brain are highly disrupted in people with schizophrenia, suggesting a link to the disease's molecular mechanisms. The study's findings could help researchers better understand schizophrenia and identify potential therapeutic targets.
Scientists at the University at Buffalo have successfully wirelessly controlled a key gene involved in human growth, opening up possibilities for new cancer treatments and mental disorder therapies. The study uses tiny photonic implants to manipulate FGFR1, a gene that plays a crucial role in human development.
Researchers suggest that viruses hiding in our DNA could be causing some of our deadliest neurological diseases. Studies link HERV reactivation to autoimmune attacks in multiple sclerosis and peripheral demyelinating disease CIDP.